We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is withdrawing two guidances on licensing blood products due to “a lack of industry interest” in pursuing either of the pilot programs, the agency said.